44
Participants
Start Date
November 30, 2002
Primary Completion Date
November 30, 2005
Study Completion Date
December 31, 2005
venlafaxine (Effexor)
Matching capsules containing venlafaxine 37.5 mg. WERE prepared by the UCLA Pharmacy for the initial phase of the study. After a one-week placebo lead-in, subjects WERE randomly assigned to receive one capsule of either venlafaxine or placebo, with the dosage increase every two days until subjects received four capsules daily (subjects achieved a dose of 150 mg. of venlafaxine after 10 days). The first dose was administered in the morning, with subsequent capsules added on a b.i.d. schedule.
placebo
Matching capsules containing placebo 37.5 mg. WERE prepared by the UCLA Pharmacy for the initial phase of the study. After a one-week placebo lead-in, subjects WERE randomly assigned to receive one capsule of either venlafaxine or placebo, with the dosage increase every two days until subjects received four capsules daily (subjects achieved a dose of 150 mg. of venlafaxine after 10 days). The first dose was administered in the morning, with subsequent capsules added on a b.i.d. schedule.
UCLA Laboratory of Brain, Behavior, and Pharmacology, Los Angeles
Collaborators (1)
Medtronic - MITG
INDUSTRY
Wyeth is now a wholly owned subsidiary of Pfizer
INDUSTRY
University of California, Los Angeles
OTHER